Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Vir Biotechnology Inc (VIR)

Vir Biotechnology Inc (VIR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,738,657
  • Shares Outstanding, K 130,040
  • Annual Sales, $ 76,370 K
  • Annual Income, $ -298,670 K
  • 60-Month Beta -1.72
  • Price/Sales 62.95
  • Price/Cash Flow N/A
  • Price/Book 7.25
Trade VIR with:

Options Overview

Details
  • Implied Volatility 99.02%
  • Historical Volatility 50.37%
  • IV Percentile 38%
  • IV Rank 6.05%
  • IV High 274.96% on 02/01/21
  • IV Low 87.68% on 08/21/20
  • Put/Call Vol Ratio 0.37
  • Today's Volume 122
  • Volume Avg (30-Day) 351
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 10,433
  • Open Int (30-Day) 13,507

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.68
  • Number of Estimates 3
  • High Estimate -0.38
  • Low Estimate -0.95
  • Prior Year -0.27
  • Growth Rate Est. (year over year) -151.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
35.00 +5.86%
on 07/15/21
47.96 -22.75%
on 06/29/21
-9.82 (-20.95%)
since 06/28/21
3-Month
35.00 +5.86%
on 07/15/21
50.00 -25.90%
on 06/25/21
-12.33 (-24.97%)
since 04/28/21
52-Week
25.31 +46.38%
on 01/04/21
141.01 -73.73%
on 01/27/21
-10.99 (-22.88%)
since 07/28/20

Most Recent Stories

More News
GSK and Vir Biotechnology Announce Joint Procurement Agreement with European Commission for COVID-19 Treatment, Sotrovimab

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced they have signed a Joint Procurement Agreement with the European Commission to supply up to 220,000 doses of...

GSK : 39.50 (-0.05%)
VIR : 37.05 (+1.67%)
Glaxo (GSK) to Report Q2 Earnings: What's in the Cards?

Glaxo's (GSK) newer respiratory and HIV drugs are likely to have driven second-quarter sales. However, sales of vaccines are likely to have been hurt by COVID-19 vaccine prioritization.

GSK : 39.50 (-0.05%)
NVS : 91.89 (+0.62%)
PFE : 43.45 (+3.21%)
VIR : 37.05 (+1.67%)
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2021 Financial Results on August 5, 2021

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2021 on Thursday, August 5, 2021.

VIR : 37.05 (+1.67%)
Regeneron's (REGN) Antibody Cocktail for COVID-19 Approved in Japan

Regeneron's(REGN) cocktail for the treatment of COVID-19 gets approval in Japan as Ronapreve.

REGN : 586.41 (+0.93%)
GSK : 39.50 (-0.05%)
RHHBY : 47.6400 (+0.72%)
VIR : 37.05 (+1.67%)
Vir Biotech (VIR) Begins Dosing in Phase II Hepatitis B Study

Vir Biotechnology (VIR) doses the first patient in a phase II study evaluating the combo of VIR-2218 plus VIR-3434 for treating patients with chronic hepatitis B virus infection.

GSK : 39.50 (-0.05%)
RGEN : 235.28 (+3.93%)
TECH : 476.76 (+0.67%)
VIR : 37.05 (+1.67%)
Vir Biotechnology Initiates Phase 2 Clinical Trial Evaluating the Combination of VIR-2218 and VIR-3434 as a Functional Cure Regimen for Chronic Hepatitis B Virus Infection

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in the Phase 2 MARCH (Monoclonal Antibody siRNA Combination against Hepatitis B) trial evaluating VIR-2218 together...

VIR : 37.05 (+1.67%)
Lilly (LLY) Stock Riding on Pipeline Developments This Year

Lilly's (LLY) shares are up this year mainly due to positive developments related to its interesting pipeline of cancer, diabetes and Alzheimer's candidates.

GSK : 39.50 (-0.05%)
BIIB : 334.18 (+0.07%)
LLY : 246.51 (+1.20%)
VIR : 37.05 (+1.67%)
Aridis' (ARDS) COVID Antibody Combo Neutralizes Delta Variant

Aridis Pharmaceuticals' (ARDS) inhaled COVID-19 dual antibody cocktail treatment, AR-712, binds and neutralizes the Delta variant of the virus. Stock rises in after-hours trading.

REGN : 586.41 (+0.93%)
LLY : 246.51 (+1.20%)
ARDS : 5.04 (+2.86%)
VIR : 37.05 (+1.67%)
Vir Biotechnology Presents New Clinical Data from Ongoing Trials of VIR-2218 and VIR-3434 in Patients with Chronic Hepatitis B Virus Infection at the International Liver Congress 2021

- Results demonstrate positive safety profiles and a reduction in HBsAg for two novel HBV therapies administrated as monotherapy or in combination with other agents -

VIR : 37.05 (+1.67%)
Glaxo (GSK)/Vir Affirm COVID-19 Drug Cuts Hospitalization/Death

Glaxo (GSK)/Vir Biotech's new data confirms that COVID-19 treatment, sotrovimab can cut hospitalization and risk of death. ViiV Healthcare inks deal with Halozyme to use its ENHANZE technology to make...

GSK : 39.50 (-0.05%)
PFE : 43.45 (+3.21%)
HALO : 41.61 (+1.14%)
VIR : 37.05 (+1.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Vir Biotechnology Inc. is a clinical-stage immunology company. It is focused on combining immunologic insights to treat and prevent serious infectious diseases. The company's development pipeline consists of product candidates targeting the hepatitis B virus, influenza A, human immunodeficiency virus...

See More

Key Turning Points

3rd Resistance Point 40.16
2nd Resistance Point 39.44
1st Resistance Point 38.25
Last Price 37.05
1st Support Level 36.34
2nd Support Level 35.62
3rd Support Level 34.43

See More

52-Week High 141.01
Fibonacci 61.8% 96.81
Fibonacci 50% 83.16
Fibonacci 38.2% 69.51
Last Price 37.05
52-Week Low 25.31

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar